Vaccine 36 (2018) 1027–1031

Contents lists available at ScienceDirect

Vaccine

journal homepage: www.elsevier.com/locate/vaccine

Short communication

Assessment of poliovirus antibody seroprevalence in polio high risk areas of West Africa

Oumar Guindo [a], Ondrej Mach [b,*], Seydou Doumbia [a], Daniel K. Ekra [c], Abdoul H. Beavogui [d], William C. Weldon [e], M. Steven Oberste [e], Roland W. Sutter [b]

[a] University Clinical Research Center (UCRC), University of Sciences, Techniques and Technology of Bamako, Bamako, Mali
[b] Polio Eradication Department, World Health Organization, Geneva, Switzerland
[c] UFR Sciences Médicales, Université Felix H. Boigny, Abidjan, Cote d'Ivoire
[d] Centre de Formation et de Recherche en Santé Rurale de Mafêrinyah, Conakry, Guinea
[e] Division of Viral Diseases, Centers for Disease Control and Prevention, Atlanta, USA

ARTICLE INFO

Article history:
Received 12 September 2017
Received in revised form 20 December 2017
Accepted 6 January 2018
Available online 19 January 2018

Keywords:
Poliomyelitis
West Africa
Eradication
Seroprevalence

ABSTRACT

We conducted a serological survey of anti-polio antibodies in polio high-risk areas of Mali, Guinea and Cote d'Ivoire to assess risk of future poliovirus outbreaks.

Random community sampling of children 6–11 and 36–48 months-old was conducted; neutralizing antibodies against poliovirus were detected using microneutralization assay.

We analysed 1059/1064 (99.5%) of enrolled children. Seroprevalence to poliovirus type 1 (PV1) across all age groups and locations ranged between 92 and 100%, for PV2 it was 77–100%, and 89–95% for PV3. PV2 seroprevalence in the younger age group in Guinea and Cote d'Ivoire was <80%. History of <4 polio vaccine doses and acute malnutrition were associated with seronegativity (OR = 2.1 CI95% = 1.5–3.1, OR = 1.8 CI95% = 1.1–3.3 respectively).

The risk of poliovirus outbreak following importation is low because of high population immunity to PV1, however, due to large cohort of PV2 seronegative children any future detection of vaccine-derived poliovirus type 2 requires urgent response to arrest rapid spread.

1. Background

Despite remarkable efforts of the Global Polio Eradication Initiative (GPEI), the last foci of endemic transmission of wild poliovirus type 1 (WPV1) remain in three endemic countries (Afghanistan, Pakistan and Nigeria) [1]. As of December 20, 2017, the total of 20 paralytic poliomyelitis cases caused by WPV1 were detected in Afghanistan and Pakistan. Albeit diminished, the risk of importation of WPVs into polio-free areas persists. Outbreaks of poliomyelitis following importations of WPVs have been described in a large number of instances [2]. In West Africa, there were several such importations leading to large epidemics in the past decade [3,4]. The outbreaks following importation of WPV1 in 2008 and another importation of WPV type 3 (WPV3) in 2010 caused more than 100 paralytic poliomyelitis cases in the West African region. In both of these instances, virus had travelled large distances from Nigeria across West Africa, passing through, and establishing circulation in the area where the countries of Mali, Cote d'Ivoire and Guinea meet: the province of Kankan in Guinea, Selingue in Mali, and Korogho in Cote d'Ivoire.

In addition to wild polioviruses, the viruses emanating from the use of oral poliovirus vaccines (OPV), so called vaccine-derived polioviruses (VDPVs) may, in rare circumstances, lead to outbreaks of paralytic poliomyelitis. This was the case in Guinea in 2015 [5]. This outbreak centred in the province of Kankan, the same area of Guinea that experienced the previous WPV outbreaks.

As a response to the WPV and VDPV outbreaks, the governments of the affected countries together with GPEI partners implemented a large number of supplementary vaccination campaigns with OPV, targeting children below 5 years of age. Between 2013 and 2016, a total of 38 campaigns were conducted in these three countries; some of the campaigns were nation-wide, while others focused only on high-risk areas.

In order to reduce the risk of future VDPV2 outbreaks, a global switch from using trivalent OPV to bivalent OPV without the type 2 component was carried out in April 2016. In addition, one dose of inactivated poliovirus (IPV) vaccine was introduced in routine immunization schedules globally. This global effort was part of

* Corresponding author at: Polio Department, World Health Organization, Avenue Appia 20, CH-1211 Genève 27, Switzerland.
E-mail address: macho@who.int (O. Mach).

https://doi.org/10.1016/j.vaccine.2018.01.022
0264-410X/

the Polio Eradication and Endgame Strategic Plan developed by GPEI [6].

The joint estimates by WHO and UNICEF of routine immunization coverage in 2016 with the third dose of OPV were 89% in Cote d'Ivoire, 72% in Guinea, and 74% in Mali. For the one dose of newly introduced IPV, they were 61%, 66% and 58% in Cote d'Ivoire, Guine, a and Mali, respectively [7].

Seroprevalence surveys have been used as a tool to evaluate polio program performance and to identify population immunity gaps, including routine serosurveys in Nigeria, India, Pakistan, and other areas [8–16].

To better understand the underlying population immunity and to assess the risk of future outbreaks of either WPVs or VDPVs, we conducted a population-based seroprevalence survey of anti-polio antibodies in those areas of Guinea, Mali, and Cote d'Ivoire that had experienced multiple poliovirus outbreaks in the recent past.

2. Methods

This was a community-based seroprevalence survey carried out in five study sites: two in Mali (Kenieroba and Selingue); two in Guinea (Kankan and Siguiri); and one in Cote d'Ivoire (Korhogo) (Fig. 1).

Children in each study site were randomly selected from two age groups: 6–11 months of age; and 36–48 months of age. A sample size of 120 children in each age group and each study site was calculated to be sufficient to detect, at the 95% confidence level, a seroprevalence point estimate with a precision of approximately ±5% assuming >90% seroprevalence and the proportion of non-consenting parents <15%.

Study assistants, together with local community health workers, enumerated children residing in the catchment areas of the health centers in the study areas and selected 120 children in each age group using a simple random sampling from existing health center records. The parents or guardians of these children were invited to the health center where, after administration of the informed consent, children were enrolled. A short questionnaire on basic demographic indicators and vaccination history was taken. Vaccination history was provided either from vaccination records or by parental recall. Weight and height were measured among the children in the older age group. Chronic malnutrition was defined as height for age z-score <−2 standard deviations from mean z-score; acute malnutrition was defined as weight for height z-score <−2 standard deviations from mean z-score.

Trained phlebotomists drew 2 mL of peripheral blood. The blood specimens were allowed to clot. Serum was separated and sera were transported to Bamako, Mali, where they were stored at −20 °C until shipment to the Centers for Disease Control and Prevention (CDC) in Atlanta, USA. The sera were tested for the presence of poliovirus neutralizing antibodies at CDC using standard neutralization assays [17]. Seropositivity was defined as reciprocal titers of poliovirus neutralizing antibodies >8. Highest reported titers were 1:1448 [17].

The study was carried out in Mali in June and July 2016, in Cote d'Ivoire in November 2016 and in Guinea in December 2016 and in January 2017. Ethical clearance was obtained by the Faculty of Medicine, Pharmacy and Dentistry of Mali, the National Ethics Committee for Health Research of Guinea and the National Ethics Committee for Research of Ivory Coast approved as well as by the Ethics Review Council of the World Health Organization, Geneva, Switzerland.

3. Results

A total of 1063 children were enrolled in the survey and 1059 of the children provided analysable blood samples, including 204 from Cote d'Ivoire, 447 from Guinea, and 408 from Mali (Table 1). There were four enrolled children who provided blood samples



Fig. 1. Map of the area of investigation (ML: Mali, IV: Cote d'Ivoire, GV: Guinea).